Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: A north central cancer treatment group study, N0675

Roxana S. Dronca, Jacob B. Allred, Domingo G. Perez, Wendy K. Nevala, Elizabeth A.T. Lieser, Michael Thompson, William J. Maples, Edward T. Creagan, Barbara A. Pockaj, Judith S. Kaur, Timothy D. Moore, Benjamin T. Marchello, Svetomir N. Markovic

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: A north central cancer treatment group study, N0675'. Together they form a unique fingerprint.

Medicine & Life Sciences